Related by context. All words. (Click for frequent words.) 69 ALK inhibitor 68 pertuzumab 68 BRAF inhibitor 67 enzastaurin 67 PI3K inhibitor 67 Imprime PGG 67 EGFR inhibitors 67 gefitinib Iressa 66 HGS ETR2 66 gemcitabine carboplatin 66 galiximab 66 VEGFR2 66 gemcitabine Gemzar 66 T#I [002] 66 pharmacodynamic PD 66 erlotinib Tarceva 66 K ras mutations 65 ganetespib 65 XmAb# 65 fulvestrant 65 CA4P 65 cetuximab Erbitux ® 65 paclitaxel Taxol 65 bortezomib Velcade 65 neratinib 65 xenograft models 65 anti angiogenic agent 65 cediranib 65 IMA# 65 receptor tyrosine kinase inhibitor 65 axitinib 65 tyrosine kinase inhibitor 65 HSP# inhibitor 65 Tarceva TM 65 pegylated liposomal doxorubicin 65 XL# inhibits 65 orally bioavailable 65 mTOR inhibition 65 cilengitide 64 CCX# 64 mTOR inhibitors 64 antisense inhibition 64 decitabine 64 cMET 64 elotuzumab 64 A3 adenosine receptor 64 Vidaza azacitidine 64 dasatinib Sprycel 64 imatinib Gleevec 64 sorafenib Nexavar 64 cetuximab Erbitux 64 CBLC# 64 Tyrima 64 seliciclib 64 oblimersen 64 IMC A# 64 liposomal formulation 64 antitumor effects 64 MGd 64 ENMD # 64 HuLuc# 64 JAK2 inhibitor 64 PRT# 64 alvespimycin 64 ZOLINZA 63 mapatumumab 63 PI3K inhibitors 63 PI3K/mTOR 63 bevacizumab Avastin ® 63 molecularly targeted 63 liposomal doxorubicin 63 Enzastaurin 63 vascular disrupting agents 63 humanised monoclonal antibody 63 FLT3 63 tanespimycin 63 EGFR tyrosine kinase inhibitors 63 pomalidomide 63 alkylating agent 63 azacytidine 63 Aplidin 63 antiangiogenic agent 63 Taxol paclitaxel 63 teriflunomide 63 HGS ETR1 63 hA# 63 oral prodrug 63 Panitumumab 63 anti EGFR antibody 63 estramustine 63 lapatinib Tykerb 63 protein kinase inhibitor 63 TroVax ® 63 docetaxel chemotherapy 63 Fulvestrant 63 DCCR 63 tubulin inhibitor 63 Angiolix 63 LY# [003] 63 INCB# [001] 63 colon carcinoma 63 MAGE A3 ASCI 63 dacetuzumab 63 anticancer activity 63 cisplatin resistant 63 Trastuzumab 63 demonstrated antitumor activity 63 Xelox 63 MEK inhibitors 63 EGFR TKIs 63 CDK inhibitor 63 HuMax CD# 63 Bezielle 62 relapsed ovarian cancer 62 fosbretabulin 62 lenalidomide dexamethasone 62 metaglidasen 62 selective modulator 62 chemosensitivity 62 trastuzumab Herceptin ® 62 LHRH receptor positive 62 cytotoxic agents 62 PARP inhibitor 62 ISIS # 62 Sorafenib 62 kinase inhibitor 62 fluoropyrimidine 62 dasatinib 62 pharmacodynamic profile 62 kinase inhibition 62 TNF α 62 antiangiogenic agents 62 vidofludimus 62 thalidomide Thalomid 62 tumorigenicity 62 Aflibercept 62 viral kinetics 62 Hsp# inhibition 62 antitumor effect 62 preclinically 62 Erlotinib 62 S/GSK# 62 Gleevec resistant 62 bleomycin 62 immune modulating 62 Targretin 62 vemurafenib 62 anti leukemic 62 Panzem R NCD 62 Sym# 62 DAVANAT 62 PEGylated Fab fragment 62 anti angiogenic agents 62 bispecific antibody 62 preclinical efficacy 62 humanized antibody 62 HGS# 62 carboplatin paclitaxel 62 antiangiogenic therapy 62 refractory prostate cancer 62 Pertuzumab 62 evaluating tivozanib 62 TLE3 62 small molecule tyrosine 62 Proxinium TM 62 effector function 62 Elotuzumab 62 HuMax EGFr 62 vorinostat 62 Panzem NCD 62 isoform selective 62 antitumor activity 62 Taxol ® 62 standard chemotherapy regimen 62 standard chemotherapy regimens 62 EGFR TKI 62 taxane chemotherapy 62 erlotinib Tarceva ® 62 OXi# 62 Akt activation 62 sorafenib Nexavar ® 62 Carfilzomib 62 EGFr 62 Doxil ® 62 cannabinor 62 AEG# 62 cyclin E 62 Onconase 62 ERBB2 62 TG# [003] 62 imatinib Gleevec ® 62 non nucleoside 61 multitargeted 61 taxane therapy 61 chemotherapeutic drug 61 HER2 positive metastatic breast 61 IgG1 antibody 61 chemopreventive agent 61 angiogenesis inhibitor 61 Vandetanib 61 Preclinical studies suggest 61 flavopiridol 61 Hedgehog inhibitor 61 histone deacetylase inhibitor 61 ixabepilone 61 olaparib 61 Lenalidomide 61 Apoptone 61 iniparib 61 amrubicin 61 Erbitux cetuximab 61 sitaxsentan 61 IFN α 61 BRAF inhibitors 61 PKC# 61 combinability 61 taxane refractory 61 pharmacokinetics PK 61 Epothilones 61 obatoclax 61 intratumoral injection 61 RG# [001] 61 paclitaxel Taxol ® 61 PLX# 61 lintuzumab 61 JAK inhibitors 61 pan HDAC inhibitor 61 T DM1 61 liposome formulation 61 MAXY G# 61 poly ADP ribose polymerase 61 Immunohistochemical analysis 61 systemically administered 61 otelixizumab 61 Symadex 61 Dasatinib 61 castration resistant prostate cancer 61 Tumor Necrosis Factor 61 ALB # 61 breast cancer subtypes 61 Bevacizumab 61 NSCLC tumors 61 complete cytogenetic response 61 chemokine receptor 61 proteasome inhibitor 61 EGF receptor 61 GRN#L 61 entinostat 61 ATL# [001] 61 investigational humanized monoclonal antibody 61 Azacitidine 61 DACH platinum 61 immunomodulation 61 Xanafide 61 HERmark assay 61 idarubicin 61 OMP #M# 61 IGF 1R 61 Archexin 61 Vitaxin 61 CCR2 61 GRN# 61 CLORETAZINE TM VNP#M 61 tumor xenograft models 61 rBChE 61 Vidaza ® 61 dose dexamethasone 61 p# Shc 61 Cytoxan 61 GW# [003] 61 Flu Cy 61 #ME# 61 bevacizumab Avastin 61 prospectively defined 61 pain palliation 61 prostate carcinoma 61 Platinol 61 mutated KRAS 60 KRAS mutations 60 imatinib therapy 60 talabostat 60 sunitinib Sutent 60 sunitinib 60 irinotecan oxaliplatin 60 CYT# potent vascular disrupting 60 IGF IR 60 predictive biomarker 60 KRAS mutation status 60 mycophenolate mofetil 60 tumor necrosis 60 peptide antigens 60 gefitinib 60 mRCC 60 Ceflatonin 60 apremilast 60 uric acid lowering 60 VEGF inhibitor 60 HQK 60 BMS # 60 FOLFIRI 60 cisplatin chemotherapy 60 nab paclitaxel 60 chemotherapy FOLFOX 60 gemcitabine chemotherapy 60 lumiliximab 60 platelet inhibitor 60 docetaxel Taxotere R 60 antimetastatic 60 antiangiogenic 60 KIT mutations 60 5 FU leucovorin 60 Factor VIIa 60 etoposide 60 Platinol ® cisplatin 60 FK# 60 EGFR mutation 60 erlotinib 60 PEG IFN 60 temsirolimus Torisel ® 60 vivo potency 60 cetuximab Erbitux R 60 trastuzumab Herceptin 60 Anticalins ® 60 Teriflunomide 60 Nicole Onetto MD 60 CIMZIA ™ 60 TTF Therapy 60 motesanib 60 CR# vcMMAE 60 sunitinib malate 60 CTLA 4 60 IAP inhibitor 60 alpha#beta# integrin 60 Afatinib 60 AVASTIN 60 survivin 60 motexafin gadolinium 60 farletuzumab 60 Zybrestat 60 pharmacodynamics PD 60 endothelin receptor 60 VEGF inhibitors 60 GFT# 60 IRX 2 60 Pharmacokinetics PK 60 selective kinase inhibitor 60 FOLFOX6 chemotherapy regimen 60 huN# DM1 60 TKI therapy 60 volociximab 60 sipuleucel T 60 metastatic castration resistant 60 mTOR inhibitor 60 Pemetrexed 60 endocrine therapies 60 Herceptin trastuzumab 60 PXD# 60 DAPT 60 Ceplene/IL-2 60 drug conjugate 60 Amplimexon 60 androgen independent 60 epithelial tumors 60 antiangiogenic activity 60 pharmacokinetic PK study 60 pancreatic adenocarcinoma 60 IFN beta 60 ON #.Na 60 crizotinib PF # 60 Squalamine 60 HER2 receptor 60 pharmacodynamic endpoints 60 Nanobody 60 docetaxel Taxotere 60 Cloretazine 60 ritonavir boosted 60 HER2 antibody 60 melphalan prednisone 60 Rituxan rituximab 60 mTOR mammalian target 60 CoFactor 60 topoisomerase 60 nilotinib 60 ZACTIMA 60 chemotherapeutic agent 60 DermaVir 60 HIV protease 60 favorable pharmacokinetic profile 60 p# inhibitor 60 Pralatrexate 60 DNA intercalator 60 imatinib resistant 60 proteasome inhibitor bortezomib 60 antitumor 60 corticosteroid dexamethasone 60 adalimumab Humira 60 daunorubicin 60 proteasome inhibitors 60 Omacetaxine 60 carcinoembryonic antigen 60 vandetanib 60 chimeric monoclonal antibody 59 radiation sensitizer 59 nucleoside analogs 59 luteinizing hormone releasing 59 PF # [001] 59 regorafenib 59 leukemia AML 59 Anticalin 59 multi kinase inhibitor 59 pimecrolimus 59 Virulizin ® 59 canakinumab 59 DFMO 59 multikinase inhibitor 59 MET amplification 59 pharmacokinetic PK 59 BRAF mutation 59 metastatic HRPC 59 adecatumumab 59 pharmacodynamic properties 59 favorable pharmacokinetic 59 endostatin 59 deforolimus 59 sorafenib tablets 59 OncoVEX 59 ponatinib 59 trabectedin 59 CD# antibody [001] 59 EGFR mutation status 59 TLR8 agonist 59 metastatic malignant 59 interferon alfa 59 neoadjuvant 59 SCH # 59 Azedra 59 interferon IFN 59 Aurora kinase 59 paclitaxel carboplatin 59 epirubicin cyclophosphamide 59 bortezomib Velcade R 59 safety tolerability pharmacokinetic 59 VAPRISOL 59 TNF inhibitor 59 bevacizumab Avastin R 59 panitumumab Vectibix 59 Asentar 59 Gefitinib 59 abiraterone 59 Temsirolimus 59 Faslodex 59 BZL# 59 Mipomersen 59 rituximab Rituxan 59 vismodegib 59 muscarinic 59 BAL# [002] 59 orally administered inhibitor 59 non squamous histology 59 Campath alemtuzumab 59 Taxotere chemotherapy 59 indibulin 59 JAK#/JAK# 59 radiolabeled monoclonal antibody 59 fluvastatin 59 chlorambucil 59 5 fluorouracil leucovorin 59 antimetabolite 59 chemoresistance 59 paricalcitol 59 cabazitaxel 59 HGS ETR1 mapatumumab 59 peptidomimetic 59 oxaliplatin Eloxatin 59 potency selectivity 59 TELINTRA 59 trastuzumab Herceptin R 59 Bortezomib 59 neurologic progression 59 INT# [002] 59 myeloproliferative disorders 59 vivo efficacy 59 Ixabepilone 59 IMC #B 59 PSMA ADC 59 antisense compounds 59 adriamycin 59 HCV protease 59 prognostic indicators 59 huC# DM4 59 alpha interferon 59 atacicept 59 JAK2 inhibitors 59 FUSILEV enhances 59 mertansine 59 Vidofludimus 59 virus HCV protease inhibitor 59 Interferon alpha 59 potent antitumor activity 59 baminercept 59 antiapoptotic 59 oral picoplatin 59 MMP inhibitors 59 milatuzumab 59 adjuvant cisplatin 59 NS4A 59 pharmacokinetic parameters 59 briakinumab 59 TNF blocker therapy 59 tumor histology 59 CIMZIA TM 59 TLR agonists 59 locoregional recurrence 59 Panzem R 59 PEGPH# 59 Tarvacin 59 Resten NG 59 AZD# 59 JAK3 59 PDE4 inhibitor 59 ocrelizumab 59 murine models 59 VNP#M 59 irinotecan chemotherapy 59 mutated KRAS gene 59 anti amnesic 59 Epirubicin 59 cisplatin gemcitabine 59 dexamethasone Decadron 59 pharmacodynamic markers 59 DXL# 59 relapsed SCLC 59 PSN# [002] 59 tumor antigen 59 siRNAs targeting 59 antimitotic 59 metastatic renal cell carcinoma 59 Telcyta 59 topotecan 59 PF # [002] 59 PEG SN# 59 Fludara 59 TNFα 59 novel anticancer 59 subcutaneously administered 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 CRLX# 58 IFN alpha 58 Annamycin 58 TKM ApoB 58 intratumoral 58 MCSP respectively 58 overlapping toxicities 58 Amrubicin 58 erythropoietic 58 TNFa 58 Anticalins R 58 cytostatic 58 siRNA mediated 58 goserelin 58 FOLFOX4 58 HCV protease inhibitors 58 TriRima 58 Pegylated Interferon 58 HuMax CD4 58 trans retinoic acid 58 imetelstat 58 5FU 58 ProSavin 58 metastatic colorectal 58 neoadjuvant chemotherapy 58 transgene expression 58 radiolabeled 58 retaspimycin 58 humanized monoclonal antibody 58 celgosivir 58 relapsed MM 58 Fludarabine 58 SUTENT 58 TELCYTA 58 CHOP chemotherapy 58 CYT# 58 ALV# 58 ZD# [001] 58 vinca alkaloid 58 immunofluorescence staining 58 low dose cytarabine 58 tamoxifen Nolvadex ® 58 tumor xenografts 58 mitomycin 58 GAMMAGARD 58 HCV replicon 58 BAY #-# 58 CYC# 58 anticancer agent 58 flutamide 58 chemoresistant 58 JAK inhibitor 58 histone deacetylase HDAC 58 KRAS mutations occur 58 PS# [001] 58 APTIVUS 58 capecitabine Xeloda 58 XELOX 58 mCRC patients 58 nucleoside analog 58 Aptivus ® 58 Fenretinide 58 radiosensitivity 58 CANCIDAS 58 docetaxel Taxotere ® 58 idraparinux 58 Tarceva erlotinib 58 GVAX 58 cisplatin vinorelbine 58 ESBA# 58 favorable tolerability 58 mGluR5 NAM 58 heavily pretreated 58 AAG geldanamycin analog 58 tumor subtypes 58 doxorubicin cyclophosphamide 58 nicardipine 58 adenoviral vectors 58 Amigal 58 eniluracil 58 selective agonist 58 thymidylate synthase TS 58 Degarelix 58 HCD# [002] 58 targeting CD# 58 MEK inhibitor 58 elesclomol 58 recurrent glioblastoma 58 Traficet EN 58 YERVOY 58 Seliciclib 58 labetuzumab 58 sorafenib Nexavar R 58 anticancer therapy 58 clodronate 58 Hsp# inhibitor 58 investigational therapies 58 Trofex 58 dasatinib Sprycel ® 58 bosutinib 58 solanezumab 58 Pimavanserin 58 antidepressant efficacy 58 Velcade bortezomib 58 adjuvant colon cancer 58 imatinib 58 GSK3B 58 PI3K/Akt pathway inhibitor 58 adalimumab 58 doxorubicin docetaxel 58 durable remissions 58 alefacept 58 chain antibody fragment 58 refractory chronic lymphocytic 58 DexaSite 58 EGFR mutation positive 58 OHR/AVR# 58 cardioprotective effects 58 lipid lowering therapies 58 microtubule inhibitor 58 vicriviroc 58 anti angiogenic drugs 58 JAK2 58 MetAP2 58 Revlimid lenalidomide 58 Cloretazine R 58 BEACOPP 58 inhaled iloprost 58 MGCD# [001] 58 zoledronate 58 telomerase inhibition 58 NSABP C 58 paclitaxel poliglumex 58 CanAg 58 investigational monoclonal antibody 58 pharmacodynamic 58 rNAPc2 58 Darusentan 58 ERCC1 58 OncoVEX GM CSF 58 chemotherapy docetaxel 58 bicalutamide 58 Fc gamma receptor 58 taxotere 58 GAP #B# 58 WT1 58 synthase TS 58 antitumoral 58 SERCA2a 58 dose cohorts 58 molecular biomarkers 58 neuroprotective properties 58 brostallicin 58 AZT zidovudine Retrovir 58 elacytarabine 58 R sorafenib tablets 58 alpha 2a 58 Neoadjuvant 58 LHRH antagonists 58 FOLFIRINOX 58 microwave hyperthermia 58 MyVax R 58 mutated K ras 58 Tasimelteon 58 statistically significant efficacy 58 temozolomide 58 ribavirin RBV 58 LE DT 58 interferon alfa 2b 58 TRX1 58 gemcitabine Gemzar ® 58 chemoradiotherapy 58 Akt inhibitor 58 Dapagliflozin 58 ALK inhibitors 58 Panzem 58 Arranon 58 TIMP 1 58 5 Fluorouracil 58 PD LID 58 LEP ETU 58 romidepsin 58 topoisomerase II inhibitor 58 EGFR antibodies 58 APOPTONE 58 VEGF Trap 58 pamidronate 58 depsipeptide 58 targeting PCSK9 58 cytokine refractory 58 rituximab monotherapy 58 tremelimumab 58 anakinra 58 Anticalin R 58 peptide conjugated 58 NEVO ™ 58 antiandrogen 58 chemotherapeutic regimens 58 liposome encapsulated 58 epigenetic therapies 58 LymphoStat B belimumab 58 relapsed ALL 58 kinase inhibitors 58 Vojo Vukovic MD Ph.D. 58 GMX# 58 SAR# [004] 58 NNRTIs 58 RGB # 57 YONDELIS 57 potently inhibited 57 inhibitor RG# 57 myeloproliferative diseases 57 novel VDA molecule 57 Exelixis XL# 57 siRNA therapeutic 57 Zolinza 57 oxidative stress inducer 57 chemotherapy hormonal therapy 57 antisense 57 R#/MEM # 57 antibody fragment 57 Myriad Flurizan 57 PDE# inhibitors 57 MAb 57 Aplidin R 57 Axitinib 57 prostate cancer AIPC 57 glucagon receptor 57 isoproterenol 57 CTAP# Capsules 57 polymerase inhibitor 57 Irinotecan 57 sargramostim 57 Combination therapy 57 GLPG# 57 selectively inhibited 57 nanomolar 57 oral clodronate 57 immunostaining 57 clinically meaningful differences 57 selective orally bioavailable 57 cytotoxic therapies 57 Pazopanib 57 IL 1ß 57 sapacitabine 57 Ixempra 57 conventional DMARDs 57 afatinib 57 Laquinimod 57 Rebif ® 57 MYDICAR ® 57 transfection efficiency 57 denileukin diftitox 57 bendamustine 57 orBec 57 aflibercept 57 TPI ASM8 57 imexon 57 Doxil 57 Apo2L 57 Omacetaxine mepesuccinate 57 interferon gamma 1b 57 oral antidiabetic 57 HDACi 57 RLY# 57 anti VEGF 57 thymalfasin 57 ELACYT 57 locoregional disease 57 gemcitabine cisplatin 57 concurrent chemoradiation 57 FOLFOX chemotherapy 57 virus AAV 57 LHRH 57 dose proportionality 57 glioma cells 57 Ocrelizumab 57 infusional 5-FU/LV 57 adjuvant tamoxifen 57 pharmacokinetic PK profile 57 dose cytarabine 57 selegiline 57 cetuximab 57 chemotherapeutic 57 trastuzumab 57 PI3 kinase inhibitors 57 XL# SAR# 57 analgesic efficacy 57 alkylating agents 57 forodesine 57 DP b# 57 epothilone 57 darapladib 57 AEGR 57 hematological indications 57 bortezomib Velcade ® 57 histologies 57 Epratuzumab 57 dacarbazine 57 azacitidine 57 fibrotic disease 57 posaconazole 57 Doxorubicin 57 selective adenosine 57 radiochemotherapy 57 zalutumumab 57 Guanilib 57 LSI #P 57 SLx 57 Vilazodone 57 grade cervical dysplasia 57 Y2 receptor 57 Melphalan 57 trabedersen 57 EndoTAG TM -1 57 multicenter Phase II 57 BRIM2 57 Romidepsin 57 dose regimens 57 vascular disrupting agent 57 humanized anti 57 cleavable linker 57 leflunomide 57 CD3 monoclonal antibody 57 letrozole Femara 57 EGFR inhibitor 57 small molecule agonists 57 nadolol 57 genotypic resistance 57 novel histone deacetylase 57 prognostic biomarker 57 steroid dexamethasone 57 allergic airway inflammation 57 Taxotere ® 57 ARIKACE ™ 57 pegylated 57 bone metastasis 57 TNF antagonist 57 TNF alpha selectively neutralizing 57 Kahalalide F 57 paclitaxel cisplatin 57 OvaRex R 57 apoptotic pathway 57 ASONEP 57 taxane resistant 57 phase IIb trial 57 sulfasalazine 57 IMGN# 57 histone deacetylase HDAC inhibitor 57 Golimumab 57 EGFR HER2 57 Eli Lilly Gemzar 57 ibandronate 57 TRAIL induced apoptosis 57 immunotoxin 57 riociguat 57 Fc fusion protein 57 anti fibrotic 57 LymphoStat B TM 57 antiresorptive 57 Hsp# Inhibitor 57 Preclinical studies 57 BNC# 57 antisense inhibitor 57 ANAVEX #-# [001] 57 chemotherapeutic agents 57 conventional chemotherapies 57 pediatric acute lymphoblastic 57 teplizumab 57 Quinamed 57 EDEMA3 trial 57 Chemophase 57 tyrosine kinase inhibitors 57 carcinoids 57 Clolar ® 57 chemotherapy gemcitabine 57 antiviral efficacy 57 tecarfarin 57 KRAS status 57 metastatic CRC 57 maximally tolerated dose 57 olmesartan 57 inhibit angiogenesis 57 tipranavir 57 temsirolimus 57 postoperative chemotherapy 57 pharmacokinetic profiles 57 iSONEP 57 TRV# [001] 57 norepinephrine reuptake inhibition 57 Capecitabine 57 alfa 2a 57 systemic antifungal 57 2 methoxyestradiol #ME# 57 MLN# 57 visilizumab 57 HDAC EGFR 57 CD# monoclonal antibody 57 Phase #b/#a trial 57 Imatinib 57 Cisplatin 57 ACZ# 57 PROCHYMAL 57 plus dexamethasone 57 nucleoside analogues 57 AP# [003] 57 chemotherapeutics 57 TBC# 57 CytoFab ™ 57 generation purine nucleoside 57 Xeloda ® 57 Hycamtin 57 selectively binds 57 Cloretazine ® 57 Exelixis compounds 57 platinum refractory 57 PARP inhibitors 57 CEQ# 57 TREANDA 56 Tarvacin TM 56 aurora kinase inhibitor 56 pharmacological chaperone 56 tubulin binding 56 alpha fetoprotein AFP 56 Lixivaptan 56 rHuPH# 56 MET inhibitor 56 ATL# [002] 56 dexrazoxane 56 gadobutrol 56 cyclophosphamide chemotherapy 56 adecatumumab MT# 56 PRTX 56 CORT # 56 Trabectedin 56 Folfox 56 NXL# 56 TACE 56 imatinib resistance 56 EGFR 56 ADP receptor antagonist 56 Camptosar ® 56 melatonin receptor 56 dosage regimens 56 haematologic 56 mg kg dose 56 cyclophosphamide Cytoxan 56 splenectomized patients 56 CLL cells 56 Neulasta ® 56 DU #b 56 oral anticancer 56 pegfilgrastim